Since Aug 1998, Weijia Fang has completed both his rotating internship and residency at the First Affiliated Hospital, Zhejiang University School of Medicine and was subsequently awarded clinical fellowships in medical oncology in FAHZU. He has accumulated broad clinical experience in the chemotherapy and biotherapy of solid malignancies, mainly in digestive system cancer. He has participated as PI in more than 20 international and domestic clinical trials involving anticancer therapies. He is the full member of ASCO and the Chinese Society of Clinical Oncology(CSCO). He has been author and co-author of several original research publications in national and international peer-reviewed scientific and medical journals.

Most up-to-date cancer immunotherapy, including CAR-T therapy for solid tumor

Novel pharmaceutical clinical studies for hepatobiliary and pancreatic cancer

Laboratory research focused on gut microbiome in cancer

Visiting scholar of Stanford hospital (2012.11)

Visiting scholar of Simon Cancer Center, University of Indianapolis. (2012.9.1~ 2012.11)

Visiting scholar of Queen Mary hospital, HongKong University (2011.9.1~ 11.30)

Editorial Board of Annals of Oncology Chinese edition (From 2019)

Editorial Board of Molecular Medicine Reports (From 2019)

Editorial Board of Artificial Intelligence in Cancer (From 2019)

Member of the American Society of Clinical Oncology (ASCO)

Council member of China Society of Clinical Oncology(CSCO)

Young Council member of China Anticancer association(CACA)

Standing member of hepatobiliary tumor expert committee of medical branch under the Western Returned Scholars Association(WRSA)